PainCeptor Achieves Development Milestones for Innovative Pain Therapeutics Programs
10-Nov-2005
The most notable of these milestones was the selection of pre-clinical lead candidates for each of PainCeptor's two key programs, ASIC 1 and NGF/P75 antagonists. These candidate selections will enable the programs to advance through the pre-clinical toxicology and pharmacokinetics stages and remain on schedule for IND and the commencement of clinical trials in 2006 and early 2007, respectively.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.